PIN21 BURDEN AND COST OF SNAKEBITE ENVENOMING: ANTIVENOM OUT OF REACH?
Aggarwal A, Pathak P, Thakur D Heron Health Private Ltd, Chandigarh, India OBJECTIVES: Anti-venom is the only specific treatment to prevent neurological disorders, amputation and death in snakebite envenoming, categorized as neglected tropical disease by WHO. Majority of victims are young and economically productive. Hence, the economic impact of their disability is considerable. We reviewed the burden and cost of snakebite envenoming: its incidence, morbidity and mortality rates, and the access to anti-venom treatment. METHODS: The information was retrieved from 1985-2009 from MEDLINE, Google Scholar and WHO website with search terms including "snakebite", "antivenom", "cost of antivenom" and "snakebite morbidity and mortality". RESULTS: Snakebite as a tropical disease causes considerable morbidity and mortality worldwide with global annual estimates for 2007 ranging from 1,200,000-5,500,000 for snakebite incidence to 42,1000-1,841,000 and 20,000-94,000 for envenoming and deaths respectively. South Asia (121,000) has the highest number of envenoming followed by Southeast Asia (111,000) and east-Sub-Saharan Africa (43,000). The price of anti-venom has typically risen by 10 fold over the last 20 years. For example, the costs to Australian hospitals of CSL polyvalent and taipan antivenoms were A$1833 and A$1577 in 2003 as compared to A$300 and A$245 in 1985, respectively. The number of anti-venom vials increases with severity (upto 5, 10 and 20 for mild, moderate and severe cases respectively) thereby increasing cost of treatment. Inadequate anti-venom supply further exaggerates this problem as the current annual need amounts to 10,000,000 vials. Incidence is higher in rural areas, where incomes are generally lower. In Nepal, out-of-pocket expenses (US$69) equal several months of income as most people have a daily incomes of 1-2 US$, besides 15 days of working incapacity period. CONCLUSIONS: The excessive cost and inadequate supply of anti-venom renders it inaccessible to most people in developing countries. Appropriate measures should be taken to prevent the clinical and economic impact of this neglected disease. (an estimated 36,000 cases in 2002) . Hepatitis B represents a relevant public health issue due to its dramatic consequences when it turns chronic, namely the associated risk of cirrhosis and hepatocellular carcinoma. The aim of this study was to estimate annual cost of disease states associated with chronic hepatitis B (CHB) from the perspective of Portuguese NHS. METHODS: We estimated the resource use to treat CHB and its disease states, namely Compensated Cirrhosis (CC), Decompensated Cirrhosis (DC), Hepatocellular Carcinoma (HCC) and Liver Transplantation follow-up (LT).A panel of 8 specialists from Portuguese NHS hospitals were surveyed using a modified Delphi technique. Data were collected for outpatient visits, laboratory tests, diagnostic and therapeutic procedures, drugs (excluding antivirals) and hospitalisations. RESULTS: The resource use for all categories increases with severity of disease. Estimated average annual costs are a1,125 for CHB, a1,761 for CC, a18,278 for DC and a26,388 for HCC. Cost for LT procedure within Portuguese DRG is estimated at a100,785, while average post-LT costs are estimated at a30,540 and a24,780 for the first and subsequent years, respectively. Costs for CHB and CC are mainly due to outpatient visits and serology tests. By contrast, inpatient days are the main driver of costs for DC (79%), HCC (50%) and post-LT in the first year after treatment (71%). Drugs represent the second major component of costs for HCC (18%), and post-LT in the first (23%) and second (72%) year, related to immunosuppressants and hepatitis B immunoglobulin respectively. CONCLUSIONS: Our study shows that annual costs of managing CHB disease states are high and increase substantially with disease severity. Both economic arguments and public health ones point to the necessity to control CHB infection and its progression.
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